P21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: Its relationship with p53, cell proliferation and survival

British Journal of Cancer

Volumn 79, Issue 5-6, 1999, Pages 895-902

  Karjalainen, J M ^a,b   Eskelinen, M J ^a   Kellokoski, J K ^b   Reinikainen, M ^b   Alhava, E M ^a   Kosma, V M ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Immunohistochemistry; Malignant melanoma; p21; p53; Prognosis; Proliferation

Indexed keywords

CYCLINE; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BLEEDING; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033067733     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690143     Document Type: Article

References (48)

1. Aaltomaa S, Lipponen P, Papinaho S and Syrjänen K (1993) Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J Cancer Res Clin Oncol 119: 288-294
2. Borresen AL, Hovig E, Smith Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ and Friend SH (1991) Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 88: 8405-8409
3. Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 12: 902-908
4. Waf1/Cip1 with PCNA. Oncogene 11: 1931-1937
5. Clark Jr WH, From L, Bernardino EA and Mihm MC (1969) The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 29: 705-726
6. Cox DR (1972) Regression models and life tables with discussion. J Stat Soc B 34: 187-192
7. Deb S, Jackson CT, Subler MA and Martin DW (1992) Modulation of cellular and viral promoters by mutant human p53 proteins found in tumour cells. J Virol 66: 6164-6170
8. Diab SG, Yu YY, Hilsenbeck SG, Allred DC and Elledge RM (1997) WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat 43: 99-103
9. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE and Hruban RH (1995) p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 147: 884-888
10. Doglioni C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F and Barbareschi M (1996) p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 179: 248-253
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumour suppression. Cell 75: 817-825
12. WAF1/cip1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919
13. Flores-Rozas H, Kelman Z, Dean FB, Pan ZQ, Harper JW, Elledge SJ, O'Donnell MO and Hurwitz J (1994) Cdk-interacting protein I directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci USA 91: 8655-8659
14. Gelsleichter L, Gown AM, Zarbo RJ, Wang E and Coltera MD (1995) P53 and mdm-2 expression in malignant melanoma: an immunohistochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumours. Modern Pathol 8: 530-535
15. Hall PA and Lane DP (1994) p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! J Pathol 172: 1-4
16. WAF1/CIP1 in pancreatic cancer. Br J Cancer 76: 299-305
17. 1 cyclin-dependent kinases. Cell 75: 805-816
18. Hiyama H, Iavarone A, LaBaer J and Reeves SA (1997) Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 14: 2533-2542
19. Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR and Fisher PB (1995) The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10: 1855-1864
20. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kohayashi T, Levin VA and Zhang W (1995) Increased levels of p21 WAF1/Cip1 in human brain tumors. Oncogene 11: 2021-2028
21. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
22. Lassam NJ, From L and Kahn HJ (1993) Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 53: 2235-2238
23. WAF1/CIP1 in malignant melanoma. Am J Pathol 149: 1813-1822
24. Melhem MF, Law JC, El-Ashmawy L, Johnson JT, Landreneau RJ, Srivastava S and Whiteside TL (1995) Assessment of sensivity and specifity of immunohistochemieal staining of p53 in lung and head and neck cancers. Am J Pathol 146: 1170-1177
25. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395
26. Moll UM, Riou G and Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262-7266
27. WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol 183: 156-163
28. Naresh KN, O'Conor GT, Soman CS, Johnson J, Advani SH, Magrath IT and Bhatia KG (1997) A study of p53 protein, proliferating cell nuclear antigen, and p21 in Hodgkin's disease at presentation and relapse. Hum Pathol 28: 549 -555
29. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R and Takahashi T (1996) Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 14: 497-502
30. Ory K, Legros Y, Auguin C and Soussi T (1994) Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496-3504
31. Podust VN, Podust LM, Goubin F, Ducommun B and Hubscher U (1995) Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21. Biochemistry 34: 8869-8875
32. Ro YS, Cooper PN, Lee JA, Quinn AG, Harrison D, Lane D, Horne CH, Rees JL and Angus B (1993) p53 protein expression in benign and malignant skin tumours. Br J Dermatol 128: 237-241
33. Sparrow LE, English DR, Heenan PJ, Dawkins HJ and Taran J (1995) Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res 5: 387-392
34. Talve L, Kainu J, Collan Y and Ekfors T (1996) Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Pathol Res Pract 192: 825-833
35. waf-1 in human cutaneous squamous cell carcinoma. Am J Pathol 149: 1139-1146
36. waf-1/CIP1 in human cutaneous malignant melanoma. J Cutan Pathol 24: 265-271
37. UICC (1987) TNM Classification of Malignant Tumours, 4th edn., Springer-Verlag, Berlin: pp. 88-90.
38. Vidal MJ, Loganzo Jr F, de Oliveira AR, Hayward NK and Albino AP (1995) Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res 5: 243-250
39. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M and Stolz W (1997) p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage 1 nodular melanomas of the skin. Histopathology 30: 57-63
40. Vojlesek B, Bontek J, Midgley CA and Lane DP (1992) An immunochemical analysis of human p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 51: 237-244
41. Waga S, Hannon GJ, Beach D and Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578
42. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, Takeda T, Shin E, Takatsuka Y, Kikkawa N, Monden T and Monden M (1997) p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 107: 684-691
43. Weiss J, Heine M, Kömer B, Pilch H and Jung EG (1995) Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 133: 23-31
44. Wynford-Thomas D (1992) P53 in tumour pathology: can we trust immunohistochemistry? J Pathol 166: 329-330
45. Yamamoto M, Takahashi H, Saitoh K, Horikoshi T and Takahashi M (1995) Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch Dermatol Res 287: 146-151
46. Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F and Tahara E (1996) Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 180: 122-128
47. WAF1/CIP1 expression by p53-independent pathways. Oncogene 12: 1557-1564
48. WAF1/CIP1 expression. Nature Genet 15: 78-82